阿达木单抗治疗自身免疫疾病的临床研究进展

Clinical study advances of adalimumab in treatment of autoimmune diseases

阿达木单抗是一种全人源单克隆抗体,可靶向作用于自身免疫疾病发病机制中起重要作用的促炎细胞因子——人肿瘤坏死因子(TNF-α)。美国和欧盟已批准阿达木单抗用于治疗中到重度类风湿关节炎、银屑病关节炎、强直性脊柱炎、中到重度克罗恩病、中到重度斑块型银屑病和中到重度多关节型幼年特发性关节炎等6个适应证。本文对阿达木单抗的作用机制、临床研究进展以及安全性等作一综述。

Adalimumab is a fully human monoclonal antibody targeted at human tumor necrosis factoralpha（TNF-α）,a important proinflammatory cytokine in the pathogenesis of autoimmune diseases.Adalimumab was approved by the United States Food and Drug Administration and by the European Medicines Agency for the treatment of moderate to severe rheumatoid arthritis,psoriatic arthritis,ankylosing spondylitis,crohn’s disease,plaque psoriasis and polyarticular juvenile idiopathic arthritis.This article reviews the mechanism of action,recent advances in clinical trials,and safety of adalimumab.